Table 1: Demographics of patients diagnosed with metastatic uveal melanoma (initial cohort).
SD = standard deviation; Min=minimum; Max=maximum; ECOG = Eastern Cooperative Oncology; LDH = lactate dehydrogenase (elevated > 241 U/L); ALP = alkaline phosphatase (elevated > 122 U/L); mm = millimeters.
| Anti-CTLA-4 + anti-PD-1 therapy (N=39) |
Anti-CTLA-4 only (N=11) |
Anti-PD-1 only (N=6) |
Other systemic or local therapy (N=6) |
None (N=9) |
Overall (N=71) |
|
|---|---|---|---|---|---|---|
| Baseline | ||||||
| Age (years) | ||||||
| Mean (SD) | 61.1 (14.6) | 58.8 (18.0) | 70.0 (14.0) | 71.2 (10.3) | 78.2 (8.55) | 64.5 (15.3) |
| Median [Min, Max] | 61.8 [20.5, 84.3] | 61.4 [16.2, 88.7] | 69.9 [46.4, 85.3] | 69.0 [55.7, 83.7] | 78.8 [58.2, 86.6] | 66.4 [16.2, 88.7] |
| Sex | ||||||
| Male | 24 (61.5%) | 6 (54.5%) | 3 (50.0%) | 3 (50.0%) | 2 (22.2%) | 38 (53.5%) |
| Female | 15 (38.5%) | 5 (45.5%) | 3 (50.0%) | 3 (50.0%) | 7 (77.8%) | 33 (46.5%) |
| Race | ||||||
| Other | 2 (5.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (2.8%) |
| White or Caucasian | 37 (94.9%) | 10 (90.9%) | 5 (83.3%) | 6 (100%) | 9 (100%) | 67 (94.4%) |
| Unknown | 0 (0%) | 1 (9.1%) | 1 (16.7%) | 0 (0%) | 0 (0%) | 2 (2.8%) |
| Ethnicity | ||||||
| Hispanic or Latino | 1 (2.6%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.4%) |
| Non-Hispanic | 38 (97.4%) | 9 (81.8%) | 5 (83.3%) | 6 (100%) | 9 (100%) | 67 (94.4%) |
| Unknown | 0 (0%) | 2 (18.2%) | 1 (16.7%) | 0 (0%) | 0 (0%) | 3 (4.2%) |
| Months from Primary to Metastasis | ||||||
| Mean (SD) | 65.8 (59.1) | 30.3 (27.3) | 55.3 (56.0) | 41.2 (75.6) | 48.8 (38.7) | 55.2 (54.7) |
| Median [Min, Max] | 59.1 [0, 216] | 17.6 [6.40, 98.9] | 42.7 [7.47, 154] | 12.8 [0.367, 195] | 50.4 [1.87, 125] | 34.7 [0, 216] |
| ECOG Performance Status | ||||||
| 0 | 31 (79.5%) | 7 (63.6%) | 3 (50.0%) | 5 (83.3%) | 1 (11.1%) | 47 (66.2%) |
| ≥1 | 7 (17.9%) | 1 (9.1%) | 2 (33.3%) | 1 (16.7%) | 8 (88.9%) | 19 (26.8%) |
| Missing | 1 (2.6%) | 3 (27.3%) | 1 (16.7%) | 0 (0%) | 0 (0%) | 5 (7.0%) |
| First Metastatic Lesion | ||||||
| Hepatic | 29 (74.4%) | 7 (63.6%) | 6 (100%) | 6 (100%) | 8 (88.9%) | 56 (78.9%) |
| Mean (SD) | 27.7 (23.6) | 23.3 (11.2) | 22.8 (18.2) | 31.8 (20.7) | 60.6 (53.9) | 31.6 (29.4) |
| Median [Min, Max] | 17.5 [4.50, 96.0] | 23.5 [10.0, 36.0] | 16.0 [7.00, 50.0] | 28.0 [8.00, 56.0] | 80.0 [6.00, 140] | 19.0 [4.50, 140] |
| < 30 | 16 (55.2%) | 4 (57.1%) | 4 (66.7%) | 3 (50.0%) | 3 (37.5%) | 30 (53.6%) |
| ≥ 30 | 10 (34.5%) | 2 (28.6%) | 2 (33.3%) | 2 (33.3%) | 4 (50.0%) | 20 (35.7%) |
| Missing | 3 (10.3%) | 1 (14.3%) | 0 (0%) | 1 (16.7%) | 1 (12.5%) | 6 (10.7%) |
| Extrahepatic | 10 (25.6%) | 4 (36.4%) | 0 (0%) | 0 (0%) | 1 (11.1%) | 15 (21.1%) |
| LDH (U/L) | ||||||
| Mean (SD) | 257 (163) | 188 (44.6) | 240 (54.9) | 340 (137) | 822 (1290) | 311 (449) |
| Median [Min, Max] | 197 [119, 873] | 177 [137, 295] | 251 [163, 312] | 321 [232, 570] | 262 [198, 3450] | 208 [119, 3450] |
| Normal | 19 (48.7%) | 9 (81.8%) | 2 (33.3%) | 2 (33.3%) | 2 (22.2%) | 34 (47.9%) |
| Elevated | 11 (28.2%) | 1 (9.1%) | 3 (50.0%) | 3 (50.0%) | 4 (44.4%) | 22 (31.0%) |
| Missing | 9 (23.1%) | 1 (9.1%) | 1 (16.7%) | 1 (16.7%) | 3 (33.3%) | 15 (21.1%) |
| ALP (U/L) | ||||||
| Mean (SD) | 91.9 (53.0) | 86.3 (23.3) | 87.0 (63.7) | 94.4 (22.4) | 133 (82.3) | 96.2 (53.8) |
| Median [Min, Max] | 75.0 [36.0, 302] | 86.5 [55.0, 127] | 60.0 [41.0, 193] | 91.0 [73.0, 120] | 120 [52.0, 313] | 79.0 [36.0, 313] |
| Normal | 28 (71.8%) | 9 (81.8%) | 4 (66.7%) | 5 (83.3%) | 4 (44.4%) | 50 (70.4%) |
| Elevated | 5 (12.8%) | 1 (9.1%) | 1 (16.7%) | 0 (0%) | 4 (44.4%) | 11 (15.5%) |
| Missing | 6 (15.4%) | 1 (9.1%) | 1 (16.7%) | 1 (16.7%) | 1 (11.1%) | 10 (14.1%) |
| Last Follow-Up | ||||||
| Disposition | ||||||
| Alive | 8 (20.5%) | 0 (0%) | 0 (0%) | 1 (16.7%) | 1 (11.1%) | 10 (14.1%) |
| Deceased | 31 (79.5%) | 11 (100%) | 6 (100%) | 5 (83.3%) | 8 (88.9%) | 61 (85.9%) |